Form 8-K IDEAYA Biosciences, Inc. For: Dec 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
GSK terminates collaboration agreement with IDEAYA Biosciences
December 5, 2025 4:26 PM ESTGlaxoSmithKline notified IDEAYA Biosciences Inc. (NASDAQ: IDYA) on December 4, 2024, of its decision to terminate their collaboration, option and license agreement originally signed on June 15, 2020.
The termination will become effective 90 days after GSK's written notice. During this transition period, GSK will transfer two clinical... More



